The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy
- PMID: 26864273
- PMCID: PMC5070917
- DOI: 10.1586/1744666X.2016.1152888
The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy
Abstract
Bruton's tyrosine kinase (BTK) mediates B cell signaling and is also present in innate immune cells but not T cells. BTK propagates B cell receptor (BCR) responses to antigen-engagement as well as to stimulation via CD40, toll-like receptors (TLRs), Fc receptors (FCRs) and chemokine receptors. Importantly, BTK can modulate signaling, acting as a "rheostat" rather than an "on-off" switch; thus, overexpression leads to autoimmunity while decreased levels improve autoimmune disease outcomes. Autoreactive B cells depend upon BTK for survival to a greater degree than normal B cells, reflected as loss of autoantibodies with maintenance of total antibody levels when BTK is absent. This review describes contributions of BTK to immune tolerance, including studies testing BTK-inhibitors for treatment of autoimmune diseases.
Keywords: B lymphocyte signaling; BTK inhibitors; Bruton’s tyrosine kinase; autoimmune inflammatory arthritis; autoimmunity; systemic lupus erythematosus; type 1 diabetes.
Figures


Similar articles
-
Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.Front Immunol. 2019 Jan 30;10:95. doi: 10.3389/fimmu.2019.00095. eCollection 2019. Front Immunol. 2019. PMID: 30761150 Free PMC article.
-
Enhanced Expression of Bruton's Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis.J Immunol. 2016 Jul 1;197(1):58-67. doi: 10.4049/jimmunol.1600208. Epub 2016 May 25. J Immunol. 2016. PMID: 27226091
-
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.Drugs. 2021 Sep;81(14):1605-1626. doi: 10.1007/s40265-021-01592-0. Epub 2021 Oct 5. Drugs. 2021. PMID: 34609725 Free PMC article. Review.
-
Bruton's tyrosine kinase is activated upon CD40 stimulation in human B lymphocytes.Immunobiology. 2002 Oct;206(4):432-40. doi: 10.1078/0171-2985-00192. Immunobiology. 2002. PMID: 12437073
-
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.Crit Rev Immunol. 2018;38(1):17-62. doi: 10.1615/CritRevImmunol.2018025184. Crit Rev Immunol. 2018. PMID: 29717662 Review.
Cited by
-
2025 update on clinical trials in immune thrombocytopenia.Am J Hematol. 2024 Nov;99(11):2178-2190. doi: 10.1002/ajh.27448. Epub 2024 Aug 6. Am J Hematol. 2024. PMID: 39105413 Review.
-
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.Blood. 2019 Feb 28;133(9):952-961. doi: 10.1182/blood-2018-07-862953. Epub 2018 Dec 13. Blood. 2019. PMID: 30545835 Free PMC article.
-
A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects.Clin Transl Sci. 2022 Jun;15(6):1507-1518. doi: 10.1111/cts.13271. Epub 2022 Apr 3. Clin Transl Sci. 2022. PMID: 35301810 Free PMC article. Clinical Trial.
-
Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.Mol Med. 2019 Jan 15;25(1):3. doi: 10.1186/s10020-018-0069-7. Mol Med. 2019. PMID: 30646846 Free PMC article.
-
CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis.JCI Insight. 2021 Dec 22;6(24):e146362. doi: 10.1172/jci.insight.146362. JCI Insight. 2021. PMID: 34784299 Free PMC article.
References
-
- Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8. First report describing humoral immunodeficiency in a male child with a disease later termed x-linked agammablobulinemia (XLA) and attributed to Bruton’s tyrosine kinase difficiency. - PubMed
-
- Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, Conley ME, Cunningham-Rundles C, Ochs HD. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85:193–202. - PubMed
-
- Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, Conley ME. The health status and quality of life of adults with X-linked agammaglobulinemia. Clinical immunology. 2006;118:201–8. - PubMed
-
- Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226–33. The first of two seminal papers identifying the B cell tyrosine kinase deficient in XLA, later named Bruton’s tyrosine kinase. - PubMed
-
- Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279–90. One of two seminal papers identifying B cell tyrosine kinase deficient in XLA, later named Bruton’s tyrosine kinase. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials